Paul Daruwala's Insider Trades & SAST Disclosures
Paul Daruwala's most recent trade in Cidara Therapeutics Inc was a trade of 16,199 Common Stock done at an average price of $0.7 . Disclosure was reported to the exchange on Sept. 12, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Paul Daruwala.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.68 per share. | 12 Sep 2022 | 16,199 | 221,099 (0%) | 0% | 0.7 | 11,095 | Common Stock |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 50,000 | 237,298 (0%) | 0% | 0 | Common Stock | |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 132,000 | 182,531 (0%) | 0% | 0 | Common Stock | |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 120,000 | 120,000 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.06 per share. | 05 Jan 2021 | 2,868 | 49,724 (0%) | 0% | 2.1 | 5,908 | Common Stock |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2021 | 1,400 | 51,124 (0%) | 0% | 0 | Common Stock | |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.66 per share. | 05 Jan 2021 | 593 | 50,531 (0%) | 0% | 2.7 | 1,577 | Common Stock |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2020 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges